^
    2d
    Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=42, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Jakafi (ruxolitinib)
    3d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    3d
    ATLAS: A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (clinicaltrials.gov)
    P2/3, N=192, Not yet recruiting, GlaxoSmithKline
    New P2/3 trial
    |
    Ojjaara (momelotinib)
    3d
    Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elzonris (tagraxofusp-erzs) • Vonjo (pacritinib)
    4d
    STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms. (PubMed, Virchows Arch)
    Entrectinib was administered, and an excellent response was observed. This case emphasizes the relevance of performing NGS in cases with unusual clinicopathological findings to identify potential treatment options. Importantly, the morphology deviated from the classic fibrosarcoma-like appearance described in most adult NTRK3-fused neoplasms and broadens the morphological spectrum in which these neoplasms should be considered.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • STRN (Striatin) • CD163 (CD163 Molecule) • CD34 (CD34 molecule) • CD68 (CD68 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • F13A1 (Coagulation Factor XIII A Chain)
    |
    NTRK fusion
    |
    Rozlytrek (entrectinib)
    4d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, University of Michigan Rogel Cancer Center | N=39 --> 20
    Enrollment change
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    5d
    POSTPONE: Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Medical College of Wisconsin | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    Vonjo (pacritinib)
    5d
    A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1 trial
    6d
    RUX-HAPLO: Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov)
    P1/2, N=24, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    6d
    Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom. (PubMed, Br J Haematol)
    Ruxolitinib-based regimens, particularly combined with azacitidine, showed acceptable activity in AP (median OS 27.2 months). IC carried high rates of febrile neutropenia and sepsis; venetoclax was associated with prolonged cytopenias. This study confirms the poor prognosis of MPN-AP/BP, the absence of a unified UK consensus approach and the need for improved therapies and prospective studies to determine optimal treatment approaches for this challenging cohort.
    Journal • HEOR • Real-world evidence
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • Jakafi (ruxolitinib)
    9d
    PACIFICA: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov)
    P3, N=407, Active, not recruiting, Swedish Orphan Biovitrum | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Oct 2028
    Enrollment closed • Trial completion date
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • hydroxyurea
    10d
    TRUX-LST: Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, University of Zurich | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker